SCHEMBL6501877

SCHEMBL6501877

Cc1cc(C(=O)Nc2ccc(NCCc3ccccn3)cc2)c(-c2ccc(F)cc2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CTNNB1 P35222 2/20 0.49
TCF7L2 Q9NQB0 2/20 0.49
NAMPT P43490 2/20 0.48
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
POLB P06746 1/20 0.44
TSHR P16473 1/20 0.44
GCGR P47871 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CNR1 P21554 1/20 0.42
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490460 0.93 L3MBTL1 (0.47) HTTKDM4EMEN1MAPTKMT2A
SCHEMBL6498735 0.93 RAB9A (0.46) HTTKDM4EMEN1GAAMAPT
SCHEMBL6489543 0.91 CNR1 (0.53) KDM4EGAACTNNB1TCF7L2RAB9A
SCHEMBL6497765 0.90 SMO (0.51)
SCHEMBL6490637 0.89 CTNNB1 (0.54) HTTKDM4EMEN1GAAMAPT
SCHEMBL6488546 0.89 CTNNB1 (0.54) HTTKDM4EMEN1GAAMAPT
SCHEMBL6487583 0.89 HTT (0.52) HTTKDM4EMEN1GAAMAPT
SCHEMBL6502209 0.87 CTNNB1 (0.50) HTTKDM4EMEN1GAAMAPT
SCHEMBL6792583 0.87 KMT2A (0.56) HTTKDM4EMEN1GAAMAPT
SCHEMBL6490335 0.86 CNR1 (0.52) HTTKDM4EMEN1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HTT 2574/4885KDM4E 2286/4885MEN1 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.